Oncology is a branch of science that
investigates cancer cells. The oncology devices market comprises medical
devices that help in the diagnosing and treating of cancer diseases.
Cancer screening and detection at an early stage are crucial for the
successful treatment of cancer.
Based on device type, the oncology
devices market can be classified into brachytherapy devices and
endoscopic devices. The endoscopic devices segment is projected to
account for a major share of the market due to growing preference for
these devices among doctors for screening of the infected site, which
helps in the early detection of cancer. In terms of application, the
oncology devices market can be segmented into external radiation beam
therapy, systemic radiation therapy, and the brachytherapy. The external
radiation beam therapy segment is expected to grow at a significant
rate during the forecast period as the therapy effectively works on
cancerous cells and shrinks tumors in a short span of time. In terms of
end-user, the oncology devices market can be divided into hospitals and
research institutes. The hospitals segment is expected to hold a
considerable share of the market during the forecast period due to rise
in rate of hospitalization for cancer treatment and a wide range of
services offered by hospitals under one roof.
Report Overview @ https://www.transparencymarketresearch.com/oncology-devices-market.html
Growth of the oncology devices market is
majorly driven by rise in demand for these devices from the ever-growing
number of patients affected with different types of cancer, such as,
breast, colorectal, and lung cancer. According to a report published by
WHO, 2018, lung cancer is the predominant among cancers and caused
approximately 1.69 million deaths in 2015. Increase in consumption of
tobacco products in developing nations, particularly in Brazil, India,
China, is a major cause of lung cancer in the world. However, high cost
of oncology devices, stringent approval processes required for products,
and side-effects of the therapy, such as local swelling, local
bruising, etc. are anticipated to hamper the global oncology devices
market in the next few years.
Request Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1145
In terms of region, the global oncology
devices market can be divided into North America, Europe, Asia Pacific,
Latin America, and Middle East & Africa. North America dominates the
global oncology devices market. The region is projected to account for a
significant share of the global oncology devices market during the
forecast period due to rise in incidence of cancer. According to the
National Cancer Institute, in 2017, almost 1.73 million new cancer cases
were diagnosed in the U.S. Moreover, in 2017, an estimated 15,270
children and adolescents under 19 years of age were diagnosed with
cancer. Growth in cancer population and availability of favorable
reimbursement policies for diagnosis of cancer are the key factors
anticipated to drive the oncology devices market in Europe from 2018 to
2026. Increase in prevalence of cancer among the tobacco-consuming
population and rise in adoption of advanced diagnostic tools in the
health care system in Asia Pacific are anticipated to fuel the oncology
devices market in the region during the forecast period. Moreover, rise
in adoption rate of advanced devices in hospitals and well-developed
hospital infrastructure in countries such as Japan and China are
attracting market players to these countries. Rise in disposable income
of people, growing incidence of cancer and availability of modern
diagnostic procedures, and favorable health care infrastructure are
likely to augment the oncology devices market in Middle East &
Africa during the forecast period.
Request for TOC @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=1145
Major players operating in the global
oncology devices market include Eckert & Ziegler BEBIG, Oncura Inc,
GE Healthcare, Medtronic plc, Varian Medical Systems, Inc., Elekta AB
(pub), Theragenics Corporation, and Accuray Incorporated.
No comments:
Post a Comment